Edwards Lifesciences Co. (NYSE:EW) Position Reduced by American Century Companies Inc.

American Century Companies Inc. reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 37.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,166,057 shares of the medical research company’s stock after selling 684,027 shares during the quarter. American Century Companies Inc.’s holdings in Edwards Lifesciences were worth $86,323,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of EW. Abacus Planning Group Inc. grew its stake in shares of Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock worth $2,977,000 after purchasing an additional 140 shares during the last quarter. Bowman & Co S.C. grew its position in Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after buying an additional 148 shares during the last quarter. Moors & Cabot Inc. increased its holdings in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock valued at $4,041,000 after buying an additional 152 shares in the last quarter. Pegasus Asset Management Inc. lifted its position in shares of Edwards Lifesciences by 0.4% during the 4th quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock valued at $3,156,000 after acquiring an additional 159 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC boosted its stake in shares of Edwards Lifesciences by 1.9% during the 4th quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after acquiring an additional 162 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 400 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now owns 22,588 shares of the company’s stock, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Piper Sandler lifted their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Barclays upped their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Finally, Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Trading Up 1.4 %

Shares of NYSE:EW opened at $71.43 on Tuesday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $41.99 billion, a PE ratio of 10.25, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm has a fifty day moving average price of $71.43 and a 200 day moving average price of $70.42.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.